ISU ABXIS Co Ltd (086890):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ISU ABXIS Co Ltd (086890) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8056
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ISU ABXIS Co Ltd (ISU ABXIS), a subsidiary of ISU Chemical Co Ltd is a biotechnology company that discovers and develops diagnostic products and therapeutic antibodies. The company’s products include fabagal, abcertin, and clotinab. It offers clinical labs, in vitro diagnostics, chemotherapy response assay, genetic testing and tissue microarray programs, among others. ISU ABXIS also provides research and development programs for encompassing novel antigen screening, lead development and manufacturing process. The company’s antibodies are used for the treatment of heart diseases, mechanism disorders, enzyme treatment, cancer patients, autoimmune and inflammatory diseases, among others. ISU ABXIS is headquartered in Seongnam, South Korea.

ISU ABXIS Co Ltd (086890) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ISU ABXIS Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Isu Abxis Enters into Co-Development Agreement with Merck 11
PH&T Enters Into Commercialization Agreement With Isu Abxis For Zoledronic Acid 12
Licensing Agreements 13
Isu Abxis Amends its Licensing Agreement with Catalyst Biosciences for Factor IX Therapeutics 13
Equity Offering 15
ISU ABXIS Raises USD26 Million in Rights Offering of Shares 15
Isu Abxis Raises USD27.2 Million in Rights Offering of Shares 16
Isu Abxis Raises USD18 Million in Private Placement of Shares 17
Isu Abxis Raises USD14.4 Million in Private Placement of Shares 18
ISU ABXIS Co Ltd – Key Competitors 19
ISU ABXIS Co Ltd – Key Employees 20
ISU ABXIS Co Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISU ABXIS Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
ISU ABXIS Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isu Abxis Enters into Co-Development Agreement with Merck 11
PH&T Enters Into Commercialization Agreement With Isu Abxis For Zoledronic Acid 12
Isu Abxis Amends its Licensing Agreement with Catalyst Biosciences for Factor IX Therapeutics 13
ISU ABXIS Raises USD26 Million in Rights Offering of Shares 15
Isu Abxis Raises USD27.2 Million in Rights Offering of Shares 16
Isu Abxis Raises USD18 Million in Private Placement of Shares 17
Isu Abxis Raises USD14.4 Million in Private Placement of Shares 18
ISU ABXIS Co Ltd, Key Competitors 19
ISU ABXIS Co Ltd, Key Employees 20
ISU ABXIS Co Ltd, Other Locations 21
ISU ABXIS Co Ltd, Subsidiaries 21

List of Figures
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ISU ABXIS Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ISU ABXIS Co Ltd (086890):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orix Corporation:企業の戦略・SWOT・財務分析
    Orix Corporation - Strategy, SWOT and Corporate Finance Report Summary Orix Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Guangzhou R&F Properties Co Ltd:企業の戦略・SWOT・財務情報
    Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PepsiCo Inc:企業のM&A・事業提携・投資動向
    PepsiCo Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PepsiCo Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Lekoil Ltd (LEK):企業の財務・戦略的SWOT分析
    Summary Lekoil Ltd (Lekoil) is an oil and gas exploration and production company with interests in Nigeria and Namibia. The company owns oil and gas exploration and production properties such as Otakikpo marginal field, Nigeria Dahomey Basin OPL310 and Nigeria Dahomey Basin OPL 325 in Nigeria, and B …
  • Uranium Energy Corp:企業の戦略・SWOT・財務情報
    Uranium Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Uranium Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • The Walt Disney Company:戦略・SWOT・企業財務分析
    The Walt Disney Company - Strategy, SWOT and Corporate Finance Report Summary The Walt Disney Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sypris Solutions, Inc.:企業の戦略・SWOT・財務分析
    Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • NetApp Inc:企業の戦略・SWOT・財務情報
    NetApp Inc - Strategy, SWOT and Corporate Finance Report Summary NetApp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Annaly Capital Management Inc:戦略・SWOT・企業財務分析
    Annaly Capital Management Inc - Strategy, SWOT and Corporate Finance Report Summary Annaly Capital Management Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Energy Recovery Inc (ERII):企業の財務・戦略的SWOT分析
    Energy Recovery Inc (ERII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • N.V. Nationale Borg-Maatschappij:企業の戦略・SWOT・財務情報
    N.V. Nationale Borg-Maatschappij - Strategy, SWOT and Corporate Finance Report Summary N.V. Nationale Borg-Maatschappij - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • AyoxxA Biosystems GmbH:医療機器:M&Aディール及び事業提携情報
    Summary AyoxxA Biosystems GmbH (AyoxxA) is a life science tools company that provides protein analysis solutions. The company offers multiple detection kits, cytokine detection kits, human inflammation kits, mouse inflammation kits, and human opthalmology kits. Its services include complete testing …
  • Chiyoda Corporation:企業の戦略・SWOT・財務情報
    Chiyoda Corporation - Strategy, SWOT and Corporate Finance Report Summary Chiyoda Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Development Bank of Southern Africa:電力:M&Aディール及び事業提携情報
    Summary Development Bank of Southern Africa (DBSA) offers various leading and infrastructure development financial services. Its service offering includes debt limited non-recourse lending, mezzanine finance, and promotion of inter-regional integration and co-operation. It offers implementation serv …
  • Trina Solar Ltd:企業の戦略的SWOT分析
    Trina Solar Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Faron Pharmaceuticals Oy (FARN):企業の財務・戦略的SWOT分析
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that develops treatments for unmet medical needs. The company is developing pipeline products with a focus on vascular damage, acute organ traumas and cancer immunotherapy. It offers Clevegen, a humanized Clever-1 …
  • Chattem Inc:企業の戦略・SWOT・財務情報
    Chattem Inc - Strategy, SWOT and Corporate Finance Report Summary Chattem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • American Tower Corporation:企業の戦略・SWOT・財務情報
    American Tower Corporation - Strategy, SWOT and Corporate Finance Report Summary American Tower Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cavitation Technologies Inc (CVAT):企業の財務・戦略的SWOT分析
    Summary Cavitation Technologies Inc (Cavitation) is an energy service company that develops processing technologies. The company processes fluidic mixtures, liquids, emulsions and suspended solids. Its technology uses hydrodynamic cavitation that comprise fluid’s vaporization and growth, pulsation, …
  • SEAS-NVE Holding AS:企業の戦略的SWOT分析
    SEAS-NVE Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆